123 related articles for article (PubMed ID: 1432610)
1. Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: analysis of factors determining their concentrations in hair.
Uematsu T; Matsuno H; Sato H; Hirayama H; Hasegawa K; Nakashima M
J Pharm Sci; 1992 Oct; 81(10):1008-11. PubMed ID: 1432610
[TBL] [Abstract][Full Text] [Related]
2. The measurement of haloperidol and reduced haloperidol in hair as an index of dosage history.
Matsuno H; Uematsu T; Nakashima M
Br J Clin Pharmacol; 1990 Feb; 29(2):187-94. PubMed ID: 2306410
[TBL] [Abstract][Full Text] [Related]
3. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
Chang WH; Shieh YS; Liu HC; Jann MW; Chien CP
Eur Neuropsychopharmacol; 1994 Jun; 4(2):119-26. PubMed ID: 7919941
[TBL] [Abstract][Full Text] [Related]
4. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients.
Nayak RK; Doose DR; Nair NP
J Clin Pharmacol; 1987 Feb; 27(2):144-50. PubMed ID: 3680566
[TBL] [Abstract][Full Text] [Related]
5. Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients.
Huang HF; Jann MW; Tseng YT; Chung MC; Chien CP; Chang WH
Psychiatry Res; 1995 Jul; 57(2):101-8. PubMed ID: 7480377
[TBL] [Abstract][Full Text] [Related]
6. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
7. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
[TBL] [Abstract][Full Text] [Related]
8. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia.
Huang HF; Jann MW; Wei FC; Chang TP; Chen JS; Juang DJ; Lin SK; Lam YW; Chien CP; Chang WH
J Clin Pharmacol; 1996 Oct; 36(10):963-9. PubMed ID: 8930784
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
Lane HY; Chang WH; Chang YC; Hu OY; Lin HN; Jann MW; Hu WH
Psychiatry Res; 1997 Sep; 72(2):127-32. PubMed ID: 9335203
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia.
Eyles DW; McLennan HR; Jones A; McGrath JJ; Stedman TJ; Pond SM
Clin Pharmacol Ther; 1994 Nov; 56(5):512-20. PubMed ID: 7955815
[TBL] [Abstract][Full Text] [Related]
11. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
Wiles DH; McCreadie RG; Whitehead A
Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
[TBL] [Abstract][Full Text] [Related]
13. Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients.
Gupta SK; Kunka RL; Metz A; Lloyd T; Rudolph G; Perel JM
J Clin Pharmacol; 1995 Feb; 35(2):202-7. PubMed ID: 7751433
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.
Chang WH; Lam YW; Jann MW; Chen H
Psychopharmacology (Berl); 1992; 106(4):517-22. PubMed ID: 1579624
[TBL] [Abstract][Full Text] [Related]
15. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
Yasui N; Otani K; Kondo T; Suzuki A; Furukori H; Kaneko S; Inoue Y
Prog Neuropsychopharmacol Biol Psychiatry; 1998 Apr; 22(3):485-92. PubMed ID: 9612845
[TBL] [Abstract][Full Text] [Related]
16. Chlorpromazine in human scalp hair as an index of dosage history: comparison with simultaneously measured haloperidol.
Sato H; Uematsu T; Yamada K; Nakashima M
Eur J Clin Pharmacol; 1993; 44(5):439-44. PubMed ID: 8359180
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol.
Aravagiri M; Marder SR; Van Putten T; Marshall BD
J Chromatogr B Biomed Appl; 1994 Jun; 656(2):373-81. PubMed ID: 7987490
[TBL] [Abstract][Full Text] [Related]
18. Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics.
Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YF; Jann MW
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):105-12. PubMed ID: 8416597
[TBL] [Abstract][Full Text] [Related]
19. Monitoring haloperidol exposure in body fluids and hair of children by liquid chromatography-high-resolution mass spectrometry.
Favretto D; Stocchero G; Nalesso A; Vogliardi S; Boscolo-Berto R; Montisci M; Ferrara SD
Ther Drug Monit; 2013 Aug; 35(4):493-501. PubMed ID: 23851906
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients.
Chang WH; Hwu HG; Lane HY; Lin SK; Chen TY; Chen H; Wei HL; Lin WL; Lin HN
Psychiatry Res; 1991 Sep; 38(3):215-25. PubMed ID: 1754634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
